The presentation to the webcast – top-line data HORIZON
June 16, 2020
Oncopeptides reports positive results from full data set of Phase 2 HORIZON trial in triple-class refractory multiple myeloma patients. On June 16 at 10:00 (CET), CEO Jakob Lindberg comments on the top-line results.
The presentation in PDF is available below.